bioRxivImmunologyPreprint
Structural basis of Omicron neutralization by affinity-matured public antibodies
D. J. Sheward, P. Pushparaj, H. Das, C. Kim, S. Kim, L. Hanke, R. Dyrdak, G. M. McInerney, J. Albert, B. Murrell, G. B. Karlsson Hedestam, B. M. Hällberg
Abstract
The SARS-CoV-2 Omicron1 Variant of Concern (B.1.1.529) has spread rapidly in many countries. With a spike that is highly diverged from that of the pandemic founder, it escapes most available monoclonal antibody therapeutics2,3 and erodes vaccine protection4. A public class of IGHV3-53-using SARS-CoV-2 neutralizing antibodies5,6 typically fails to neutralize variants carrying mutations in the receptor-binding motif7-11, including Omicron. As antibodies from this class are likely elicited in most people following SARS-CoV-2 infection or vaccination, their subsequent affinity maturation is of particular interest. Here, we isolated IGHV3-53-using antibodies from an individual seven months after infection and identified several antibodies capable of broad and potent SARS-CoV-2 neutralization, extending to Omicron without loss of potency. By introducing select somatic hypermutations into a germline-reverted form of one such antibody, CAB-A17, we demonstrate the potential for commonly elicited antibodies to develop broad cross-neutralization through affinity maturation. Further, we resolved the structure of CAB-A17 Fab in complex with Omicron spike at an overall resolution of 2.6 [A] by cryo-electron microscopy and defined the structural basis for this breadth. Thus, public SARS-CoV-2 neutralizing antibodies can, without modified spike vaccines, mature to cross-neutralize exceptionally antigenically diverged SARS-CoV-2 variants.
- organism: human
- assay: proteomics
- research focus: cell type annotation
- approach: experimental assay
- approach: deep learning
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular basis of broad neutralization against SARS-CoV-2 variants including Omicron by a human antibody
- Germinal center-derived broadly neutralizing antibodies adapt to SARS-CoV-2 antigenic drift
K. Shitaoka, Y. Kawano, … T. Yasuda·bioRxiv·Jan 26, 2022
- Convergent IGHV3-53/3-66 antibodies elicited by Omicron BA.1 infection broadly neutralize emerging SARS-CoV-2 variants
Naveenchandra Suryadevara, Seth J. Zost, … James E. Crowe·bioRxiv·Aug 20, 2026
- Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
M. McCallum, N. Czudnochowski, … D. Veesler·bioRxiv·Dec 28, 2021
- Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
A. Patel, S. Kumar, … E. A. Ortlund·bioRxiv·Oct 24, 2022
- Somatic evolution of a cross-reactive germline antibody that expands its breadth to neutralize new SARS-CoV-2 variants
Huibin Lv, Ziqi Feng, … Chris Ka Pun Mok·bioRxiv·Mar 25, 2026